CAC
JSPR icon

Cowen and Company’s Jasper Therapeutics JSPR Stock Holding History

Cowen and Company’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,000
Closed -$158K – 699
2023
Q4 		$158K Sell
20,000
-39
-0.2% -$262 0.01% 225
2023
Q3 		$140K Buy
+20,039
New +$245K 0.01% 232
2021
Q1 		– Sell
-2,500
Closed -$250K – 587
2020
Q4 		$250K Sell
2,500
-1,000
-29% -$99.5K 0.02% 165
2020
Q3 		$347K Buy
+3,500
New +$350K 0.06% 163

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Cowen and Company's JSPR Position: Q1 2024 in Review

Cowen and Company sold out of Jasper Therapeutics (JSPR) in Q1 2024, closing a stake of 20,000 shares — an estimated $158K sold.

Cowen and Company first reported a position in JSPR in Q3 2020 and held it in 4 quarters. The position peaked at $347K in Q3 2020. 61 funds tracked by Wall St. Rank hold JSPR as of Q1 2024.

  • Cowen and Company reported no remaining Jasper Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cowen and Company sold 20,000 Jasper Therapeutics shares in Q1 2024, an estimated $158K.
  • Cowen and Company first reported a position in Jasper Therapeutics in Q3 2020 and held it in 4 quarters.
  • Cowen and Company's Jasper Therapeutics position peaked at $347K in Q3 2020.
  • 61 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.